Please wait while we open this resource.
K
Clinical reviews
BLEEDING RISK WITH APIXABAN VS. RIVAROXABAN IN ACUTE VENOUS THROMBOEMBOLISM
The New England Journal of Medicine
PDF202610 pages527 KB
Apixaban and rivaroxaban are the most commonly used oral anticoagulants for treating acute venous thromboembolism, yet their comparative bleeding risks remain uncertain. This international trial involved a randomized, open-label design where eligible patients were assigned to receive either apixaban or rivaroxaban for three months. The primary outcome measured was clinically relevant bleeding, and secondary outcomes included mortality rates. The study provides critical insights into the safety profiles of these anticoagulants.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
Myeloproliferative Neoplasms
Same clinical topic · Hematology
MASTOCYTOSIS
Same clinical topic · Hematology
MYELODYSPLASTIC SYNDROMES: 2023 UPDATE ON DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT
Same clinical topic · Hematology
PERIPHERAL T-CELL LYMPHOMAS
Same clinical topic · Hematology
COMPARISON OF THE INTERNATIONAL CONSENSUS AND 5TH WHO EDITION CLASSIFICATIONS OF ADULT MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
Same clinical topic · Hematology
VEXAS SYNDROME: A COMPREHENSIVE REVIEW OF PATHOGENESIS, CLINICAL SPECTRUM, AND THERAPEUTIC STRATEGIES
Same clinical topic · Hematology
IRON DEFICIENCY
Same clinical topic · Hematology
MULTIPLE MYELOMA: 2026 UPDATE ON DIAGNOSIS, RISK-STRATIFICATION AND MANAGEMENT
Same clinical topic · Hematology
ANTIDOTES FOR ANTICOAGULATION REVERSAL
Same clinical topic · Hematology